Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg in Recurrent Pregnancy Loss
NCT03174951Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Sep 2016
- Primary completion
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of immune globulin in recurrent pregnancy loss (RPL) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Changes in NK cells, T reg and Th17 cells frequency at 8 months, Changes in secretion levels of cytokines related to Treg and Th17 cells(IL-17,IL-21) at 8 months and 1 more. Started Sep 2016; status: completed.
02
Drugs
immune globulin
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT03174951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174951.